Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors

Journal of Medicinal Chemistry

Volumn 48, Issue 5, 2005, Pages 1610-1619

  Harris, Philip A ^a   Cheung, Mui ^a   Hunter III, Robert N ^a   Brown, Matthew L ^a,b   Veal, James M ^a,c   Nolte, Robert T ^a   Wang, Liping ^a   Liu, Wendy ^a,d   Crosby, Renae M ^a   Johnson, Jennifer H ^a   Epperly, Andrea H ^a   Kumar, Rakesh ^a   Luttrell, Deirdre K ^a,e   Stafford, Jeffrey A ^a,f  

^a GLAXOSMITHKLINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c Serenex Inc   (United States)

^d MEDTRONIC INC   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f Takeda San Diego Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; N [5 (ETHYLSULFONYL) 2 METHOXYPHENYL] 5 (3 PYRIDIN 2 YLPHENYL) 1,3 OXAZOL 2 AMINE; OXAZOLE DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 2 KINASE INHIBITOR; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL STRAIN HT29; CONTROLLED STUDY; DOG; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SOLUBILITY; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; X RAY CRYSTALLOGRAPHY;

ADENOSINE TRIPHOSPHATE; ANGIOGENESIS INHIBITORS; ANILINE COMPOUNDS; ANIMALS; BINDING SITES; CELL PROLIFERATION; CELLS, CULTURED; CRYSTALLOGRAPHY, X-RAY; DOGS; HUMANS; LIGANDS; MALE; MICE; MODELS, MOLECULAR; OXAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 20144376862     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049538w     Document Type: Article

References (27)

1. Folkman, J. Fundamental Concepts of the Angiogenic Process. Curr. Mol. Med. 2003, 3, 643-651.
2. Veikkola, T.; Karkkainen, M.; Claesson-Welsh, L.; Alitalo, K. Regulation of Angiogenesis via Vascular Endothelial Growth Factor Receptors. Cancer Res. 2000, 60, 203-212.
3. Glade-Bender, J.; Kandel, J. J.; Yamashiro, D. J. VEGF Blocking Therapy in the Treatment of Cancer. Expert Opin. Biol. Ther. 2003, 3, 263-276.
4. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350, 2335-2342.
5. Lu, D.; Jimenez, X.; Zhang, H.; Bohlen, P.; Witte, L.; Zhu, Z. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int. J. Cancer 2002, 97, 393-399.
6. Holash, J.; Davis, S.; Papadopoulos, N.; Groll, S. D.; Ho, L.; Russell, M.; Boland, P.; Leidich, R.; Hylton, D.; Burova, E.; Ioffe, E.; Huang, T.; Radziejewski, C.; Bailey, K.; Fandl, J. P.; Daly, T.; Wiegand, S. J.; Yancopoulos, G. D.; Rudge, J. S. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 11393-11398.
7. Bold, G.; Altman, K.-H.; Frei, J.; Lang, M.; Manley, P. W.; Traxler, P.; Weitfeld, B.; Bruggen, J.; Buschdunger, E.; Cozens, R.; Ferrari, S.; Furet, P.; Hofmann, F.; Martiny-Baron, G.; Mestan, J.; Rosel, J.; Sills, M.; Stover, D.; Acemoglu, F.; Boss, E.; Emmenegger, R.; Lasser, L.; Masso, E.; Roth, R.; Schlachter, C.; Vetterli, W.; Wyxx, D.; Wood, J. M. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinase useful as antagonists of tumor-driven angiogenesis. J. Med. Chem. 2000, 43, 2310-2323.
8. Hennequin, L. F.; Stokes, E. S.; Thomas, A, P.; Johnstone, C.; Ple, P. A.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Kendrew, J.; Curwen, J. O. Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 2002, 45, 1300-1312.
9. Mendel, D. B.; Laird, A. D.; Xin, X.; Louie, S. G.; Christensen, J. G.; Li, G.; Schreck, R. E.; Abrams, T. J.; Ngai, T. J.; Lee, L. B.; Murray, L. J.; Carver, J.; Chan, E.; Moss, K. G.; Haznedar, J. O.; Sukbuntherng, J.; Blake, R. A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J. M. In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship. Clin. Cancer Res. 2003, 9, 327-337.
10. Beebe, J. S.; Jani, J. P.; Knauth, E.; Goodwin, P.; Higdon, C.; E.; Rossi, A. M.; Emerson, E.; Finkelstein, M.; Floyd, E.; Harriman, S.; Atherton, J.; Hillerman, S.; Soderstrom, C.; Kou, K.; Grant, T.; Noe, M. C.; Foster, B.; Rastinejad, F.; Marx, M. A.; Schaeffer, T.; Whalen, P. M.; Roberts, W. G. Pharmacological Characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res. 2003, 63, 7301-7309.
11. Brown, M. L.; Cheung, M.; Dickerson, S. H.; Gauthier, C.; Harris, P. A.; Hunter, R. N.; Pacofsky, G.; Peel, M. R.; Stafford, J. A. Chemical Compounds. PCT Int. Appl., 2004, WO 2004032882.
12. Sych, E. D.; Belaya, Zh. N.; Moreiko, O. V. Synthesis of azole derivatives. IV. Reaction of aminomethyl and (alkylamino)-methyl ketones with carbon disulfide. Khim. Geterotsikl. Soedin. 1970, No. 2 282-285. (Chem. Abstr. 76: 140606).
13. Sych, E. D.; Belaya, Zh. N.; Moreiko, O. V. Synthesis of azole derivatives. IV. Reaction of aminomethyl and (alkylamino)-methyl ketones with carbon disulfide. Khim. Geterotsikl. Soedin. 1970, No. 2 282-285. (Chem. Abstr. 76: 140606).
14. Harrison, R. G. Oxazole derivatives. Ger. Offen. 1976, 2,459,-380 (Chem. Abstr. 86: 121320).
15. Harrison, R. G. Oxazole derivatives. Ger. Offen. 1976, 2,459,-380 (Chem. Abstr. 86: 121320).
16. Froeyen, P. New applications of iminophosphoranes. The preparation of β-keto carbodiimides and their rearrangement to 2-amino-1,3-oxazoles. Phosphorus, Sulfur Silicon Relat. Elements 1991, 60, 81-84.
17. Mohammadi, M.; Froum, S.; Hamby, J. M.; Schroeder, M. C.; Panek, R. L.; Lu, G. H.; Eliseenkova, A. V.; Green, D.; Schlessinger, J.; Hubbard, S. R. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 1998, 17, 5896-5904.
18. Mohammadi, M.; McMahon, G.; Sun, L.; Tang, C.; Hirth, P.; Yeh, B. K.; Hubbard, S. R.; Schlessinger, J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997, 276, 955-960.
19. Nagar, B.; Bornmann, W. G.; Pellicena, P.; Schindler, T.; Veach, D. R.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Crystal Structure of the Kinase Domain of c-Abl in Complex With the Small Molecule Inhibitors PD173955 and Imatinib (STI-571). Cancer Res. 2002, 62, 4236-4243.
20. Schindler, T.; Sicheri, F.; Pico, A.; Gazit, A.; Levitzki, A.; Kuriyan, J. Crystal structure of Hck in complex with & Src family-selective tyrosine kinase inhibitor. Mol. Cel., 1999, 3, 639-648.
21. Zhu, X.; Kim, J. L.; Newcomb, J. R.; Rose, P. E.; Stover, D. R.; Toledo, L. M.; Zhao, H.; Morgenstern, K. A. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure Fold Des. 1999, 7, 651-661.
22. Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002, 277, 46265-46272.
23. McTigue, M. A.; Wickersham, J. A.; Pinko, C.; Showalter, R. E.; Parast, C. V.; Tempczyk-Russell, A.; Gehring, M. R.; Mroczkowski, B.; Kan, C.-C.; Vllafranca, J. E.; Appelt, K. Crystal Structure of the Kinase Domain of Human Vascular Endothelial Growth Factor Receptor 2: A Key Enzyme in Angiogenesis. Structure 1999, 7, 319-330.
24. Coordinates may be obtained from the RCSB Protein data bank under accession codes 1Y6A (oxazole 39) and 1Y6B (oxazole 46).
25. Collaborative Computational Project, Number 4, The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. 1994, D50, 760-763.
26. Jones, T. A.; Bergdoll, M.; Kjeldgaard, M. O. A macromolecule modeling environment. Crystallogr. Model. Methods Mol. Des., [Pap. Symp.] Bugg, C. E., Ed.; Springer: New York, 1990; pp 189-199.
27. Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J.-S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1998, D54, 905-921.